Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Intermittent Linezolid in Pneumonia
NCT04531332Unknown
- Sponsor
- October 6 University
- Start
- Nov 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of linezolid in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) (2 arms), sponsored by October 6 University. Primary endpoints: Proportion of cured patients at 1 year and Percentage of occurrence of anemia and thrombocytopenia at 1 year. Status: unknown.
02
Drugs
linezolid
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT04531332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04531332.